1905 Audubon Ct.
Spokane, WA 99224

04-04-2019 – BIXT – Bioxytran Licensing FDA Approved Technology from MDX Lifesciences for use in Pipeline Drug Development

Bioxytran announces plans to use a revolutionary new device, the MDX Viewer, to measure the effectiveness of BXT-25 in stroke patients BOSTON, MASSACHUSETTS, April 04, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Company has entered into a definitive exclusive licensing agreement with MDX Lifesciences, Inc. (MDX).  The licensing agreement will allow Bioxytran to continue commercial development of MDX technology and develop new protocols that measure the tissue...

Read More

04-01-2019 – WDRFF – The Movie Studio Inc. Announces Strategic Partnership and Joint Venture With Wonderfilm for Asset Alignment, Co-Production and Acquisition of Two Intellectual Properties

FT. LAUDERDALE, Fla., April 01, 2019 (GLOBE NEWSWIRE) -- The Movie Studio, Inc. (OTC:MVES) www.themoviestudio.com proudly announces a Strategic Partnership and Joint Venture with Wonderfilm Media Corporation (OTC:WDRFF TSXV: WNDR) www.wonderfilm.com to align the mutually beneficial assets and associations between the publicly traded Companies. The performance covenants between the entities specifically focuses on “Above the Line” production and distribution services and associations from Wonderfilm in regard to The Movie Studio’s current intellectual properties as well as the additions of additional intellectual properties owned or controlled by Wonderfilm or its principals during the term of the agreement. In addition, the agreement cumulates the Companies associations, relationships and...

Read More

03-19-2019 – ETBI – EastGate Biotech Signs Strategic Alliance Agreement with MJ Biopharm for Insulin API Supply

Alliance with MJ Biopharm of Mumbai, India positions the company to further its plans for SEA countries for its liquid insulin mouth rinse WEST CALDWELL, NJ and TORONTO, ON, March 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- EastGate Biotech Corp. (OTC PINK: ETBI),  a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, entered into a long term strategic alliance with MJ Biopharm (www.mjgroup.co.in) for the supply of human recombinant insulin. One of the key terms of the strategic alliance agreement between EastGate and MJ Biopharm is to...

Read More

03-18-2019 – BIXT – Bioxytran, Inc. Engages Resources Unlimited NW, LLC. for Strategic Investor Relations

BOSTON, MASSACHUSETTS, March 18, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company, with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims, announced today that the Company has retained Resources Unlimited NW, LLC., a strategic investor relations agency, with a wealth of experience in biotech to manage the company’s investor relations program. “We are excited to be partnering with Resources Unlimited (RU) in our investor relations effort”, said BIXT CEO, Dr. David Platt. “This group truly understands the sector we are in...

Read More

02-25-2019 – WDRFF – Wonderfilm Congratulates Newest Partner, Impossible Dream Entertainment, On Oscar® Win For ‘Blackkklansman’ At The 91st Academy Awards

VANCOUVER, BC / ACCESSWIRE / February 25, 2019 / The Wonderfilm Media Corporation (TSX-V: WNDR), (OTC PINK: WDRFF), (FRA: 25Y), ("Wonderfilm" or "Company"), a technology, media and entertainment company, is pleased to recognize and congratulate our newest producing partners and Oscar winning duo, Shaun Redick & Yvette Yates Redick on their success of ‘BlacKkKlansman', which garnered the Best Adapted Screenplay Oscar at the 91st Academy Awards held on February 24, 2019. The award further solidifies Shaun & Yvette as industry leading producers whom are able to develop story ideas into silver screen successes. BlacKkKlansman's Oscar win and nominations are tremendous follow-ups...

Read More

11-19-2018 – ETBI – EastGate Biotech Appoints World-Renowned Diabetes Key Opinion Leader Dr. Lalit Upadhyay for Upcoming Initiatives

Key Opinion Leader spreading awareness of diabetes endorses the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / November 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of type 2 diabetes, appointed key advisor Dr. Lalit Upadhyay to be the diabetes ambassador to help drive awareness of the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients. Dr. Lalit has devoted his life messaging that managing...

Read More

11-15-2018 – TNTY – True Nature Holding Inc. Appoints Consumer and Digital Marketing Expert to Advisory Board

ATLANTA, Nov. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- True Nature Holding, Inc. (OTCQB: TNTY) (the "Company" or "True Nature") announces the appointment of John S. Stowell, age 56, to its Board of Advisors. Mr. Stowell is a senior marketing leader with deep business management expertise at both large and entrepreneurial firms. His resume includes over 25 years of brand building marketing experience from notable companies including Coca-Cola, Mitsubishi Electric Heating and Cooling, as well as Zep Cleaning Solutions. “True Nature is committed to fully addressing the ‘direct to consumer’ movement in healthcare through technology offerings. The business solutions we are...

Read More

11-02-2018 – LHGI – Lighthouse Global Holdings Inc. Completes Acquisition of PROJAGG Platform in an All Stock Transaction Press Release |

NEVADA, November 2, 2018 -- LIGHTHOUSE GLOBAL HOLDINGS, INC. (OTC: LHGI), a diversified holdings company in the real estate development, property industry and disruptive technology for more efficient and effective performance leveraging on innovative solutions, announced today that the Company has completed the acquisition of PROJAGG Platform, a sharing economy cloud platform powered by Blockchain Smart Contracts technology for $5.85 million in restricted common stock at the price of $.045. In connection with this transaction 130,000,000 shares of restricted common stock were issued to 4 parties in exchange for 100% ownership of the PROJAGG Platform, together with its pipeline of...

Read More

10-16-2018 – TNTY – True Nature Holding Expands Senior Team, Names Mr. James Crone, President and to Board of Directors Press Release |

Recognizes Importance of Digital and “Direct to Consumer” Marketing ATLANTA, Oct. 16, 2018 (GLOBE NEWSWIRE) -- True Nature Holding, Inc. (TNTY) (the "Company" or "True Nature", www.truenatureholding.com today announced that it has appointed Mr. James (“Jim”) Crone, age 54, to its Board of Directors, and to the position of President. Mr. Crone is a veteran in the marketing and sales arena with over 25 years-experience including senior positions with both large and smaller boutique advertising agency operations. He will be fully responsible for all marketing and sales responsibilities specifically, in addition to his general management responsibilities. “Jim is a perfect addition to...

Read More

10-04-2018 – TNTY – True Nature Executing On Growth With Acquisition Of Prescription Cost Controls Application Developer

ATLANTA, Oct. 04, 2018 (GLOBE NEWSWIRE) -- True Nature Holding, Inc. (OTCQB: TNTY) (the "Company" or "True Nature") today announced that it has executed a letter of intent (LOI) for the acquisition of Singularis Health, LLC (“Singularis”), a developer of healthcare information technology applications, DBA “Singularis eHealth”. Singularis is an Indianapolis-based health IT venture that provides unprecedented prescription cost and restriction transparency to Health Care Providers (HCP) at the point of care.  Singularis will enable increased cost savings and improved outcomes through higher first fill rates, improved 30 day readmission rates, better HCP productivity, and improved patient satisfaction. “Singularis is...

Read More